OKYO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
OKYO Pharma Ltd is not a strong buy at the moment for a long-term beginner investor. The technical indicators are neutral to bearish, there are no significant trading signals, and no recent news or financial data to support a strong entry point. While the analyst rating is positive with a high price target, the lack of momentum and catalysts suggests waiting for more clarity or a better opportunity.
The MACD is slightly positive but contracting, RSI is neutral at 50.151, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 1.593, with key resistance at 1.688 and support at 1.497. Overall, the technical indicators suggest a neutral to bearish trend.
Analyst Biren Amin from Piper Sandler initiated coverage with an Overweight rating and a $7 price target, citing promising Phase 2 data for its lead asset, urcosimod, which addresses a high unmet need in neuropathic corneal pain.
No significant hedge fund or insider trading activity. No recent news or congress trading data. Technical indicators do not show a strong upward trend.
No financial data available for analysis.
Positive analyst sentiment with an Overweight rating and a $7 price target from Piper Sandler, based on promising Phase 2 data and high unmet need in neuropathic corneal pain.
